IgAN
12
4
5
1
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
33.3%
4 terminated out of 12 trials
20.0%
-66.6% vs benchmark
25%
3 trials in Phase 3/4
300%
3 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (12)
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) Nephropathy
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Atacicept in Multiple Glomerular Diseases
Safety and Efficacy Study of VIS649 for IgA Nephropathy
FXS6837 for the Treatment of IgAN Patients
Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
Efficacy and Safety Study of HS-10542 for IgA Nephropathy
Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)
Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)
Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment